Featured on Forbes: AbCellera Raises $105 Million To Boost Drug Discovery Against Coronavirus And Other Diseases

“A biotech company partnering with major pharmaceutical players like Lilly on Covid-19 drug development is raising $105 million in funding to ramp up. AbCellera announced on Wednesday that it raised that sum in a Series B funding round led by OrbiMed and DCVC Bio. The investment takes the company’s total funding to about $115 million in its eighth year of operation.”

Read full coverage on Forbes.

PARTNERSHIP

Together we can make game-changing discoveries.